அங்கித் மஹாதேவியா News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from அங்கித் மஹாதேவியா. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In அங்கித் மஹாதேவியா Today - Breaking & Trending Today

Spero Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference

Spero Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

United Kingdom , Ankit Mahadevia , Ashley Robinson , Spero Therapeutics Inc , Chief Executive Officer , Spero Therapeutics , Ladenburg Thalmann Healthcare Conference , Spero Therapeutic , Relations Contact , ஒன்றுபட்டது கிஂக்டம் , அங்கித் மஹாதேவியா , ஆஷ்லே ராபின்சன் , ஸ்பீரோ சிகிச்சை இன்க் , தலைமை நிர்வாகி அதிகாரி , ஸ்பீரோ சிகிச்சை , உறவுகள் தொடர்பு ,

Spero Therapeutics Announces $40 Million Equity Investment from Pfizer Inc. and Licensing Agreement for SPR206

Nachrichtenquelle: globenewswire
| 01.07.2021, 00:46 |
110
|
0
Spero grants Pfizer rights to develop, manufacture, and commercialize SPR206 in ex-U.S. and ex-Asia territories in exchange for potential development and commercial milestone payments and
royalties.
CAMBRIDGE, Mass., June 30, 2021 (GLOBE NEWSWIRE) Spero Therapeutics, Inc. (Nasdaq: SPRO) – a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and
commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases – today announced that Pfizer Inc. (NYSE: PFE) has made a $40 million
equity investment in Spero as part of the Pfizer Breakthrough Growth Initiative, a program focused on funding innovative science to meet patient needs. The two parties have also ....

Ankit Mahadevia , Chief Executive Officer , அங்கித் மஹாதேவியா , தலைமை நிர்வாகி அதிகாரி ,

Spero Therapeutics Announces Fourth Quarter and Full-Year 2020 Operating Results and Provides ...

Spero Therapeutics Announces Fourth Quarter and Full-Year 2020 Operating Results and Provides ...
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.

United States , United Kingdom , Tamara Joseph , Ankit Mahadevia , Sath Shukla , Us Department Of Defense , Department Of Defense , Cubist Pharmaceuticals Inc , Trademark Office , Invivo Therapeutics Holdings Corp , Spero Therapeutics Inc , Millendo Therapeutics Inc , Ziopharm Oncology Inc , Biomedical Advanced Research , Drug Administration , Mayne Pharma Ltd , Development Authority , Department Of The Army , Exchange Commission , Enzyvant Therapeutics Ltd , Government Agency Research , Transkaryotic Therapies Inc , Chief Executive Officer , Upcoming Milestones , Qualified Infectious Disease Product , Fast Track ,

Spero Therapeutics Provides Update on SPR720 Phase 2a Clinical Trial

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Spero Therapeutics Provides Update on SPR720 Phase 2a Clinical Trial
Spero Therapeutics, Inc.February 5, 2021 GMT
CAMBRIDGE, Mass., Feb. 05, 2021 (GLOBE NEWSWIRE) Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that the United States Food and Drug Administration (FDA) informed Spero that a clinical hold has been placed on its Phase 2a clinical trial of SPR720, Spero’s investigational oral antimicrobial agent being evaluated in patients with nontuberculous mycobacterial pulmonary disease (NTM-PD). ....

United Kingdom , United States , Ankit Mahadevia , Exchange Commission , Infectious Disease Society Of America , Drug Administration , Spero Therapeutics Inc , United States Food , Safety Review Board , Infectious Disease Society , Qualified Infectious Disease Product , Fast Track , Media Contact , Investor Relations , ஒன்றுபட்டது கிஂக்டம் , ஒன்றுபட்டது மாநிலங்களில் , அங்கித் மஹாதேவியா , பரிமாற்றம் தரகு , தொற்று நோய் சமூகம் ஆஃப் அமெரிக்கா , ஸ்பீரோ சிகிச்சை இன்க் , ஒன்றுபட்டது மாநிலங்களில் உணவு , பாதுகாப்பு விமர்சனம் பலகை , தொற்று நோய் சமூகம் , தகுதி தொற்று நோய் ப்ராடக்ட் , வேகமாக டிராக் , மீடியா தொடர்பு ,

Spero Therapeutics Announces Appointment of Sath Shukla as Chief Financial Officer

Spero Therapeutics Announces Appointment of Sath Shukla as Chief Financial Officer
December 17, 2020 08:00 ET
| Source:
Spero Therapeutics, Inc.
Spero Therapeutics, Inc.
Cambridge, Massachusetts, UNITED STATES
CAMBRIDGE, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced the appointment of Satyavrat “Sath” Shukla, CFA, as Chief Financial Officer, effective as of January 4, 2021.
“Sath is an ideal fit for our management team given his experience leading financial strategy and executing within both clinical and commercial stage companies,” said Ankit Mahadevia, M.D., Chief Executive Officer of Spero Therapeutics. “He has extensive strat ....

United Kingdom , Ankit Mahadevia , Stephen Dipalma , Satyavrat Sath Shukla , Yale University , Ziopharm Oncology Inc , Exchange Commission , Principal At Cornerstone Research , Harvard University , Spero Therapeutics Inc , Hayes Bartlett Inc , Compensation Committee Of Spero Board Directors , Chief Financial Officer , Chief Executive Officer , Interim Chief Financial Officer , Ziopharm Oncology , Vice President , Global Head , Corporate Finance , Vertex Pharmaceuticals , Cornerstone Research , Chartered Financial Analyst , Compensation Committee , Spero Therapeutics , Equity Incentive Plan , Nasdaq Listing Rule ,